Key takeaways

• The melanocortin system comprises five Class A GPCRs (MC1R–MC5R) and a shared set of POMC-derived peptide ligands.
• All five melanocortin system subtypes couple primarily to Gs and raise cAMP, but differ sharply in tissue distribution.
• MC2R is the outlier: it responds only to ACTH and requires the MRAP accessory protein to traffic and signal.
• Agouti signalling protein and AgRP act as endogenous antagonists, a rare feature among GPCR families.
• PT-141 is a cyclic heptapeptide studied as a non-selective agonist with research interest at MC3R and MC4R.
• KPV, the C-terminal tripeptide of ?-MSH, sits on the anti-inflammatory arm of the melanocortin system.

What is the melanocortin system?

POMC is a precursor protein cleaved by prohormone convertases into several bioactive fragments. The peptides that emerge from that processing — the three melanocyte-stimulating hormones and adrenocorticotropic hormone — share a conserved His-Phe-Arg-Trp core motif that forms the pharmacophore recognised by the receptors. That shared motif is what gives the melanocortin system its unusual pharmacological breadth.

Apart from MC2R, the subtypes are stimulated by the same endogenous agonists, none of which is fully subtype-selective. Cryo-EM work has since clarified how subtype preference is encoded in the binding pocket rather than in the ligand, and a survey of the tool compounds used to interrogate the melanocortin system documents how much of the field’s early mapping depended on synthetic analogues rather than native peptides.

• Receptor class: five Class A (rhodopsin-like) seven-transmembrane G protein-coupled receptors.
• Primary transduction: Gs ? adenylyl cyclase ? cAMP ? protein kinase A, with ?-arrestin recruitment as a second arm.
• Shared pharmacophore: the His-Phe-Arg-Trp message sequence common to ?-, ?- and ?-MSH.
• Sequence homology: excluding MC1R, the remaining four subtypes share roughly 56–74% sequence similarity yet mediate distinct functions.
• Endogenous antagonism: agouti signalling protein at MC1R and AgRP at MC3R/MC4R, acting as competitive antagonists or inverse agonists.
• Accessory proteins: MRAP1 and MRAP2 modulate surface expression and signalling, most critically for MC2R.

Mechanism of action across the melanocortin system

Agonist binding stabilises an active receptor conformation that engages G?s. The resulting cAMP rise is the canonical readout in nearly every in vitro assay of the melanocortin system, and cAMP accumulation remains the standard endpoint for characterising new ligands. Divalent calcium ions occupy a conserved site in several subtypes and behave as a co-factor for high-affinity agonist binding — a detail that matters when buffer composition is optimised.

Because the endogenous ligands are promiscuous, selectivity within the melanocortin system is largely a property of where a receptor is expressed rather than what binds it. That distinction underpins the comparative table below.

• POMC is cleaved into ?-MSH, ?-MSH, ?-MSH and ACTH by tissue-specific prohormone convertases.
• The His-Phe-Arg-Trp motif inserts into the orthosteric pocket formed by transmembrane helices 3, 6 and 7.
• Ca²? coordination within the pocket stabilises agonist binding at several subtypes.
• G?s activation drives adenylyl cyclase and cAMP production.
• PKA phosphorylates downstream effectors including CREB, altering transcriptional programmes.
• GRK phosphorylation and ?-arrestin recruitment produce desensitisation and a distinct signalling branch.
• AgRP and agouti protein compete at the same pocket, lowering constitutive and agonist-driven tone.

Melanocortin system receptor subtypes: MC1R to MC5R

The table below summarises how the five subtypes are conventionally distinguished. Tissue distribution is the practical axis on which research models are chosen.

• MC4R is the most heavily studied central subtype and the target of the MC4R-selective agonist setmelanotide in rare genetic obesity research.
• Cryo-EM structures of MC3R and MC5R revealed a receptor-specific groove explaining ?-MSH’s relative preference for MC3R.
• MC2R’s dependence on MRAP makes it the only subtype that cannot be studied in a standard heterologous expression line without co-transfection.
• MC1R loss-of-function variants are the best-characterised natural experiment in the melanocortin system, producing the red-hair/fair-skin phenotype.
• Because ?-MSH is non-selective, subtype attribution requires selective antagonists such as SHU9119 or subtype-null models.

Research applications across the melanocortin system

Work on the melanocortin system is framed as mechanistic and preclinical. The directions below are documented in the peer-reviewed literature and are described strictly as research context, not as outcomes attributable to any product.

• Receptor–ligand structure–activity relationship (SAR) mapping using ?-MSH analogues.
• cAMP accumulation and ?-arrestin recruitment assays for biased-signalling characterisation.
• Cryo-EM and crystallographic determination of active and inactive receptor complexes.
• Energy-balance circuit mapping in rodent models using MC4R agonists and antagonists.
• Investigation of MC1R and MC5R signalling in cultured immune cell populations.
• Pigmentation biology and UV-response signalling in melanocyte culture.
• Comparative pharmacology of cyclic versus linear analogues, indexed across thousands of records in the ?-MSH-derived peptide literature on PubMed.

Two research tools at opposite ends of the melanocortin system: PT-141 and KPV

What makes the melanocortin system interesting for a research catalogue is that a single precursor peptide gives rise to tools at very different points in the network. PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide derived from the ?-MSH analogue Melanotan II. It is characterised as a non-selective melanocortin receptor agonist, with most research attention directed at its activity at the centrally expressed MC3R and MC4R subtypes. Our PT-141 research guide covers that profile in more depth.

At the other end sits KPV (Lys-Pro-Val), the C-terminal tripeptide of ?-MSH, supplied as one of four components in the KLOW research blend alongside GHK-Cu, TB-500 and BPC-157. KPV is notable because it lacks the motif required for canonical binding anywhere in the melanocortin system, yet retains much of the anti-inflammatory profile reported for the full hormone — one reason it is treated as a mechanistically separate research question rather than a simple ?-MSH substitute. The KPV research guide expands on that distinction.

• PT-141: cyclic heptapeptide; research interest concentrated at MC3R/MC4R.
• KPV: linear tripeptide ?-MSH(11–13); no canonical melanocortin system pharmacophore.
• Together they illustrate receptor-mediated versus non-canonical signalling within one peptide lineage.
• Neither substitutes for the other in an experimental design; the readouts differ entirely.
• Both are supplied strictly as lyophilized research-grade material, not for human consumption.

Handling, reconstitution, and quality verification

Peptide integrity determines whether a melanocortin system binding result means anything. The handling requirements below apply to every compound discussed here.

• Store lyophilized peptide at ?20 °C, protected from light and moisture; long-term storage at ?80 °C is preferable.
• Reconstitute with bacteriostatic or sterile water directed down the vial wall, never injected directly onto the powder pellet.
• Swirl gently to dissolve; vortexing and vigorous shaking can shear peptide bonds and promote aggregation.
• Store reconstituted solution at 2–8 °C and record the reconstitution date; avoid repeated freeze–thaw cycles.
• Confirm identity and purity against a batch-specific certificate of analysis before any assay work begins.
• NeuroPept Labs COA validity is verifiable at freedomdiagnosticstesting.com using the Accession Number, Client ID, or Search Code shown in the product images.

Our overview of HPLC and mass spectrometry in peptide purity testing explains what those documents should actually show.

Considerations for experimental design

Because the endogenous ligands are non-selective, most confounds in melanocortin system work come from attributing an effect to the wrong subtype.

• Expression system: heterologous cell lines versus native tissue, and whether MRAP co-expression is required.
• Selectivity controls: subtype-selective antagonists such as SHU9119, plus receptor-null comparisons.
• Buffer composition, particularly calcium concentration, given its role in agonist binding.
• Assay endpoint: cAMP accumulation, ?-arrestin recruitment, or downstream transcriptional readout.
• Peptide concentration verification by analytical measurement rather than assumed vial content.
• Solvent and vehicle matching across all treatment and control arms.

Clean melanocortin system data depends on knowing exactly what is in the vial. Verified high-purity material — such as the research-grade PT-141 supplied with third-party analytical documentation — removes one of the largest sources of unexplained variance before an experiment begins.

Frequently asked questions

What is the melanocortin system?

It is the network of POMC-derived peptide hormones — ?-MSH, ?-MSH, ?-MSH and ACTH — together with the five G protein-coupled receptors MC1R through MC5R that they activate. It regulates pigmentation, steroidogenesis, energy balance and inflammatory signalling depending on which subtype is engaged.

How many receptors are in the melanocortin system?

Five: MC1R, MC2R, MC3R, MC4R and MC5R. All are Class A G protein-coupled receptors that signal principally through Gs and cAMP, and all except MC2R respond to the shared set of melanocyte-stimulating hormones.

Why is MC2R different from the other subtypes?

MC2R binds only ACTH and does not respond to the melanocyte-stimulating hormones. It also requires the melanocortin receptor accessory protein MRAP to reach the cell surface and signal, which means it cannot be studied in a standard expression line without co-transfection.

Which receptor subtype does PT-141 act on?

PT-141 (Bremelanotide) is characterised as a non-selective melanocortin receptor agonist, with research attention concentrated on its activity at the centrally expressed MC3R and MC4R subtypes. It is a cyclic heptapeptide derived from the ?-MSH analogue Melanotan II.

Is KPV a melanocortin receptor agonist?

Not in the canonical sense. KPV is the C-terminal tripeptide of ?-MSH and lacks the His-Phe-Arg-Trp sequence motif required for binding the known melanocortin receptors, yet published work reports that it retains much of the anti-inflammatory activity of the full hormone through mechanisms that are still being characterised.

Is the melanocortin system approved for human use?

No. The compounds discussed on this page are supplied for in vitro and laboratory research only. They are not approved for human use, are not medicines, and are not for human or veterinary consumption.